Combined-modality staging for localized adenocarcinoma of the prostate

ONCOLOGY

Volumn 15, Issue 8, 2001, Pages 1049-1059

  D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADENOCARCINOMA; BIOPSY; BLOOD; CANCER STAGING; HUMAN; MALE; METHODOLOGY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; PROSTATECTOMY; REVIEW; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; BIOPSY; HUMANS; MALE; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0035432641     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. D'Amico AV, Whittington, R, Malkowicz SB, et al: Combined-modality staging of prostate carcinoma and its utility in defining pathologic stage: The role of endorectal coil magnetic resonance imaging. Urology 49:23-30, 1997.
2. Kupelian P, Katcher J, Levine HS, et al: Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 137:1043-1052, 1997.
3. D'Amico AV, Whittington R, Kaplan I, et al: Equivalent biochemical failure free survival after external-beam radiation therapy or radical prostatectomy in patients with a pretreatment PSA > 4-20 ng/mL. Int J Radiat Oncol Biol Phys 32:293-306, 1995.
4. Zagars GK, Pollack A, Kavadi VS, et al: Prostate specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32:293-306, 1995.